Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Jan 17;6(1):7.
doi: 10.1186/s40249-016-0214-x.

Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies

Affiliations
Meta-Analysis

Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies

Kelemu Tilahun Kibret et al. Infect Dis Poverty. .

Abstract

Background: Anti-tuberculosis drug resistance is a major public health problem that threatens the progress made in tuberculosis care and control worldwide. Treatment success rates of multidrug-resistant tuberculosis (MDR-TB) is a key issue that cannot be ignored. There is a paucity of evidence that assessed studies on the treatment of MDR-TB, which focus on the effectiveness of the directly observed treatment, short-course (DOTS)-Plus program. Therefore, it is crucial to assess and summarize the overall treatment outcomes for MDR-TB patients enrolled in the DOTS-Plus program in recent years. The purpose of this study was to thus assess and summarize the available evidence for MDR-TB treatment outcomes under DOTS-Plus.

Methods: A systematic review and meta-analysis of published literature was conducted. Original studies were identified using the databases MEDLINE®/PubMed®, Hinari, and Google Scholar. Heterogeneity across studies was assessed using the Cochran's Q test and I2 statistic. Pooled estimates of treatment outcomes were computed using the random effect model.

Results: Based on the 14 observational studies included in the meta-analysis, it was determined that 5 047 patients reported treatment outcomes. Of these, the pooled prevalence, 63.5% (95% CI: 58.4-68.5%) successfully completed full treatment (cured or treatment completed) with a pooled cure rate of 55.6%, whereas 12.6% (95% CI: 9.0-16.2%) of the patients died, 14.2% (95% CI: 11.6-16.8%) defaulted from therapy, and 7.6% (95% CI: 5.6-9.7%) failed therapy. Overall 35.4% (95% CI: 30-40.8%) of patients had unsuccessful treatment outcomes. An unsatisfactorily high percentage 43% (95% CI: 32-54%) of unsuccessful treatment outcomes was observed among patients who were enrolled in standardized treatment regimens.

Conclusion: This study revealed that patients with MDR-TB exhibited a very low treatment success rate compared to the World Health Organization 2015 target of at least 75 to 90%. The high default rate observed by conducting this literature review could possibly explain the spread of the MDR-TB strain in various populations. A better treatment success rate was observed among patients in individualized treatment regimens than in standardized ones. Conducting further individual-based meta-analysis is recommended to identify potential factors for defaulting treatment using large-scale and multi-center studies.

Keywords: DOTS-Plus; Multidrug resistance; Multidrug-resistant tuberculosis; Treatment outcomes; Tuberculosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow chart showing the selection of studies for systematic review (identification and screening, eligible and included studies). NB: Articles may have been excluded for more than one reason
Fig. 2
Fig. 2
Forest plot of the 14 observational studies that quantitatively assessed successful MDR-TB treatment outcomes under DOTS-Plus
Fig. 3
Fig. 3
Forest plot of the 14 observational studies that quantitatively assessed unsuccessful MDR-TB treatment outcomes under DOTS-Plus
Fig. 4
Fig. 4
Forest plot of the 13 observational studies that quantitatively assessed successful MDR-TB treatment outcomes under DOTS-Plus by treatment regimen
Fig. 5
Fig. 5
Forest plot of the 13 observational studies that quantitatively assessed unsuccessful MDR-TB treatment outcomes under DOTS-Plus by treatment regimen

References

    1. World Health Organization update on multi-drug resistance tuberculosis, October 2014. http://www.who.int/tb/challenges/mdr/. Accessed 12 Dec 2015.
    1. Nathanson E, Lambregts-van Weezenbeek C, Rich ML, Gupta R, Bayona J, Blöndal K, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis. 2006;12(9):1389. doi: 10.3201/eid1209.051618. - DOI - PMC - PubMed
    1. Central TB Division, Directorate General of Health Services, Ministry of Health & Family Welfare. DOTS-Plus Guidelines 2006. Nirman Bhavan, New Delhi: Revised National Tuberculosis Control Programme; pp. 1–46.
    1. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis. 2004;8:1382–1384. - PubMed
    1. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line anti-tuberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472–1477. doi: 10.1164/rccm.200206-626OC. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources